- 同
- DHEAS
- 関
- Dehydroepiandrosterone sulfate
- 同
- 硫酸デヒドロエピアンドロステロン
Wikipedia preview
出典(authority):フリー百科事典『ウィキペディア(Wikipedia)』「2014/12/04 21:43:48」(JST)
[Wiki en表示]
Dehydroepiandrosterone sulfate |
|
|
IUPAC name
[(3S,8R,9S,10R,13S,14S)-10,13-Dimethyl-17-oxo-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-yl] hydrogen sulfate
|
|
Identifiers |
Abbreviations |
DHEAS |
CAS number |
651-48-9 Y |
PubChem |
12594 |
Jmol-3D images |
Image 1 |
-
C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O) CC=C4[C@@]3(CC[C@@H](C4)OS(=O)(=O)O)C
|
Properties |
Molecular formula |
C19H28O5S |
Molar mass |
368.49 g/mol |
Except where noted otherwise, data are given for materials in their standard state (at 25 °C (77 °F), 100 kPa) |
Y (verify) (what is: Y/N?) |
Infobox references |
|
|
Dehydroepiandrosterone sulfate or DHEA-S is a metabolite of dehydroepiandrosterone (DHEA).
Contents
- 1 Synthesis
- 2 Use as biomarker
- 3 Therapeutic use
- 4 Reference ranges
- 5 See also
- 6 References
Synthesis
Dehydroepiandrosterone sulfate is produced by the addition of a sulfate group, catalyzed by the sulfotransferase enzymes SULT1A1 and SULT1E1, which also produce estrone sulfate from estrone. DHEA sulfate can also be back-converted to DHEA through the action of steroid sulfatase.
In the zona reticularis layer of the adrenal cortex, DHEA-sulfate is generated by SULT2A1.[1] This layer of the adrenal cortex is thought to be the primary source of serum DHEA-sulfate. DHEA sulfate levels decline as a person ages as the reticularis layer diminishes in size.
Use as biomarker
Dehydroepiandrosterone sulfate levels above 1890 micromol/L or 700-800 µg/dL are highly suggestive of adrenal dysfunction because DHEA-S is made exclusively by the adrenal glands.[2][3] Presence of DHEA-S is therefore used to rule out ovarian or testicular origin of excess androgen.
Therapeutic use
The Endocrine Society recommends against the therapeutic use of DHEA sulfate in both healthy women and those with adrenal insufficiency, as their role is not clear from studies performed so far.[4] The routine use of DHEAS and other androgens is discouraged in the treatment of women with low androgen levels due to hypopituitarism, adrenal insufficiency, menopause due to ovarian surgery, glucocorticoid use, or other conditions associated with low androgen levels; this is because there are limited data supporting improvement in signs and symptoms with therapy and no long-term studies of risk.[4]
In otherwise elderly women, in whom an age-related fall DHEA sulfate may be associated with menopausal symptoms and reduced libido, DHEA sulfate supplementation cannot currently be said to improve outcomes.[5]
Reference ranges
Reference ranges for dehydroepiandrosterone sulfate in females[6]
Tanner stage and average age |
Lower limit |
Upper limit |
Unit |
Tanner stage I |
>14 days |
16 |
96 |
µg/dL |
Tanner stage II |
10.5 years |
22 |
184 |
Tanner stage III |
11.6 years |
<15 |
296 |
Tanner stage IV |
12.3 years |
17 |
343 |
Tanner stage V |
14.5 years |
44 |
332 |
18–29 years |
44 |
332 |
30–39 years |
31 |
228 |
40–49 years |
18 |
244 |
50–59 years |
<15 |
200 |
> or =60 years |
<15 |
157 |
Reference ranges for dehydroepiandrosterone sulfate in males[6]
Tanner stage and average age |
Lower limit |
Upper limit |
Unit |
Tanner stage I |
>14 days |
<15 |
120 |
µg/dL |
Tanner stage II |
11.5 years |
<15 |
333 |
Tanner stage III |
13.6 years |
<15 |
312 |
Tanner stage IV |
15.1 years |
29 |
412 |
Tanner stage V |
18.0 years |
89 |
457 |
18–29 years |
89 |
457 |
30–39 years |
65 |
334 |
40–49 years |
48 |
244 |
50–59 years |
35 |
179 |
> or =60 years |
25 |
131 |
See also
- Polycystic ovary syndrome
References
- ^ Rainey WE, Nakamura Y (February 2008). "Regulation of the adrenal androgen biosynthesis". J. Steroid Biochem. Mol. Biol. 108 (3-5): 281–6. doi:10.1016/j.jsbmb.2007.09.015. PMC 2699571. PMID 17945481.
- ^ Somani N, Harrison S, Bergfeld WF (2008). "The clinical evaluation of hirsutism". Dermatologic therapy 21 (5): 376–91. doi:10.1111/j.1529-8019.2008.00219.x. PMID 18844715.
- ^ "Polycystic Ovarian Syndrome Workup". eMedicine. 25 October 2011. Retrieved 19 November 2011.
- ^ a b Wierman, Margaret E.; Arlt, Wiebke; Basson, Rosemary; Davis, Susan R.; Miller, Karen K.; Murad, Mohammad H.; Rosner, William; Santoro, Nanette. "Androgen Therapy in Women: A Reappraisal: An Endocrine Society Clinical Practice Guideline". The Journal of Clinical Endocrinology & Metabolism 99 (10): 3489–3510. doi:10.1210/jc.2014-2260. PMID 25279570.
- ^ Elraiyah, Tarig; Sonbol, Mohamad Bassam; Wang, Zhen; Khairalseed, Tagwa; Asi, Noor; Undavalli, Chaitanya; Nabhan, Mohammad; Altayar, Osama; Prokop, Larry; Montori, Victor M.; Murad, Mohammad Hassan. "The Benefits and Harms of Systemic Dehydroepiandrosterone (DHEA) in Postmenopausal Women With Normal Adrenal Function: A Systematic Review and Meta-analysis". The Journal of Clinical Endocrinology & Metabolism 99 (10): 3536–3542. doi:10.1210/jc.2014-2261. PMID 25279571.
- ^ a b Dehydroepiandrosterone Sulfate (DHEA-S), Serum at Mayo Foundation For Medical Education And Research. Retrieved July 2012
Steroid hormones (and metabolic intermediates)
|
|
Precursors |
- Cholesterol
- 22R-Hydroxycholesterol
- 20α,22R-Dihydroxycholesterol
|
|
Corticosteroids |
Glucocorticoids
|
- Corticosterone
- Cortisol
- Cortisone
- Cortodoxone/Deoxycortisol
- Deoxycorticosterone
- 17-Hydroxypregnenolone
- 17-Hydroxyprogesterone
- Pregnenolone
- Progesterone
|
|
Mineralocorticoids
|
- Aldosterone
- Corticosterone
- Cortisol
- Cortodoxone/Deoxycortisol
- Deoxycorticosterone
- 5α-Dihydroaldosterone
- 17-Hydroxypregnenolone
- 17-Hydroxyprogesterone
- 18-Hydroxycorticosterone
- 18-Hydroxydeoxycorticosterone
- Pregnenolone
- Progesterone
|
|
|
Sex steroids |
Androgens
|
- 3α-Androstanediol
- Androstenediol
- Androstenedione
- Androsterone
- DHEA
- DHEA sulfate
- Dihydrotestosterone
- Epiandrosterone
- Epitestosterone
- 16-Hydroxyandrostenedione
- 16-Hydroxy-DHEA
- 16-Hydroxy-DHEA sulfate
- Testosterone
|
|
Estrogens
|
- 3β-Androstanediol
- DHEA
- Estetrol
- Estradiol
- Estrone
- Estriol
- 2-Hydroxyestrone
- 16-Hydroxyestrone
|
|
Progestogens
|
- Deoxycorticosterone
- DHDOC
- 5α-Dihydroprogesterone
- 17-Hydroxyprogesterone
- Progesterone
|
|
|
Neurosteroids |
- Allopregnanolone
- 3α-Androstanediol
- Androsterone
- Corticosterone
- DHC
- DHDOC
- DHEA
- DHEA sulfate
- DHP
- Deoxycorticosterone
- Etiocholanolone
- 17-Hydroxypregnenolone
- 17-Hydroxyprogesterone
- Isopregnanolone
- Pregnanolone
- Pregnenolone
- Pregnenolone sulfate
- Progesterone
- THB
- THDOC
|
|
Others |
- Vitamin D: 7-Dehydrocholesterol
- Calcidiol/Calcifediol
- Calcitriol
- Cholecalciferol
|
|
GABAergics
|
|
Receptor
(ligands)
|
GABAA
|
- Agonists: Main site: Bamaluzole
- Gaboxadol
- Ibotenic acid
- Isoguvacine
- Isonipecotic acid
- Muscimol (Amanita muscaria)
- Picamilon
- Piperidine-4-sulfonic acid
- Progabide
- Quisqualamine
- SL 75102
- Thiomuscimol
- Tolgabide; Positive allosteric modulators: Alcohols
- Barbiturates
- Benzodiazepines
- Carbamates
- Chlormezanone
- Clomethiazole
- Imidazoles
- Kavalactones (kava)
- Lanthanum
- Loreclezole
- Neuroactive steroids
- Niacin/niacinamide
- Nonbenzodiazepines (β-carbolines, cyclopyrrolones, imidazopyridines, pyrazolopyrimidines, etc.)
- Phenols
- Piperidinediones
- Propanidid
- Pyrazolopyridines
- Quinazolinones
- ROD-188
- Skullcap
- Stiripentol
- Valerenic acid (valerian)
Note: See here for a full list of GABAA PAMs.
- Antagonists: Main site: Bicuculline
- Coriamyrtin
- Dihydrosecurinine
- Gabazine
- Hydrastine
- Hyenachin (mellitoxin)
- Pitrazepin
- Securinine
- Sinomenine
- Thiocolchicoside
- Tutin; Negative allosteric modulators: 17-Phenylandrostenol
- α5IA (LS-193,268)
- Anisatin
- β-Lactams (penicillins, cephalosporins, carbapenems)
- Bemegride
- Bilobalide
- Cicutoxin
- Cyclothiazide
- DHEA
- DHEA-S
- DMCM
- FG-7142 (ZK-31906)
- Fipronil
- Flumazenil
- Fluoroquinolones (e.g., ciprofloxacin)
- Flurothyl
- Furosemide
- Iomazenil (123I)
- Isopregnanolone (sepranolone)
- L-655,708
- Leptazol
- Lindane
- Morphine
- Naloxone
- Naltrexone
- Oenanthotoxin
- Pentetrazol (metrazol)
- Phenylsilatrane
- Picrotoxin (picrotin, picrotoxinin)
- Pregnenolone sulfate
- PWZ-029
- Radequinil
- RG-1662
- Ro15-4513
- Ro4938581
- Sarmazenil
- Suritozole
- TB-21007
- Terbequinil
- TETS
- Thujone
- U-93631
- Zinc
- ZK-93426
|
|
GABAB
|
- Agonists: Main site: 1,4-Butanediol
- Aceburic acid
- Baclofen
- GBL
- GHB
- GHV
- GVL
- Lesogaberan
- Phenibut
- Picamilon
- Progabide
- SKF-97,541
- Tolgabide; Positive allosteric modulators: BHF-177
- BHFF
- BSPP
- CGP-7930
- GS-39783
Antagonists: Main site: CGP-35348
- Phaclofen
- Saclofen
- SCH-50911
|
|
GABAρ
|
- Agonists: Main site: CACA
- CAMP
- GABOB
- N4-Chloroacetylcytosine arabinoside
- Picamilon
- Progabide
- Tolgabide
Antagonists: Main site: Bilobalide
- TPMPA; Positive allosteric modulators: Neuroactive steroids
|
|
|
Transporter
(blockers)
|
GAT
|
- CI-966
- Deramciclane
- EF-1502
- Gabaculine
- Guvacine
- Nipecotic acid
- NNC 05-2090
- SKF-89976A
- SNAP-5114
- Tiagabine
|
|
VGAT
|
- Nipecotic acid
- Vigabatrin
|
|
|
Enzyme
(inhibitors)
|
GAD
|
|
|
GABA-T
|
- 3-Hydrazinopropionic acid
- Aminooxyacetic acid
- Gabaculine
- Isoniazid
- Phenelzine
- Phenylethylidenehydrazine
- Rosmarinic acid (lemon balm)
- Sodium valproate
- Valnoctamide
- Valproate pivoxil
- Valproate semisodium (divalproex sodium)
- Valproic acid
- Valpromide
- Vigabatrin
|
|
|
Others
|
- Precursors: 1,4-Butanediol
- γ-Hydroxybutaldehyde
- GHB
- Glutamate
- Glutamine
|
|
Glutamatergics
|
|
Receptor
(ligands)
|
AMPA
|
- Agonists: 5-Fluorowillardiine
- AMPA
- Domoic acid
- Quisqualic acid; Positive allosteric modulators: Aniracetam
- Cyclothiazide
- CX-516
- CX-546
- CX-614
- CX-691
- CX-717
- Diazoxide
- HCTZ
- IDRA-21
- LY-392,098
- LY-404,187
- LY-451,395
- LY-451,646
- LY-503,430
- Org 26576
- Oxiracetam
- PEPA
- Piracetam
- Pramiracetam
- S-18986
- Sunifiram
- Unifiram
Antagonists: ATPO
- Barbiturates
- BGG492
- Caroverine
- CNQX
- DNQX
- GYKI-52466
- NBQX
- Perampanel
- Talampanel
- Tezampanel
- Topiramate; Negative allosteric modulators: GYKI-53,655; Unclassified/Unsorted antagonists: Cyclopropane
|
|
NMDA
|
- Agonists: Glutamate/active site competitive agonists: Aspartate
- Glutamate
- Homoquinolinic acid
- Ibotenic acid
- NMDA
- Quinolinic acid
- Tetrazolylglycine; Glycine site agonists: ACBD
- ACPC
- ACPD
- Alanine
- CCG
- Cycloserine
- DHPG
- Fluoroalanine
- Glycine
- GLYX-13
- HA-966
- L-687,414
- Milacemide
- NRX-1074
- Sarcosine
- Serine
- Tetrazolylglycine; Polyamine site agonists: Acamprosate
- Spermidine
- Spermine
Antagonists: Competitive antagonists: AP5 (APV)
- AP7
- CGP-37849
- CGP-39551
- CGP-39653
- CGP-40116
- CGS-19755
- CPP
- LY-233,053
- LY-235,959
- LY-274,614
- MDL-100,453
- Midafotel (d-CPPene)
- NPC-12,626
- NPC-17,742
- PBPD
- PEAQX
- Perzinfotel
- PPDA
- SDZ-220581
- Selfotel; Noncompetitive antagonists: ARR-15,896
- Caroverine
- Dexanabinol
- FPL-12495
- FR-115,427
- Hodgkinsine
- Magnesium
- MDL-27,266
- NPS-1506
- Psychotridine
- Zinc; Uncompetitive pore blockers: 2-MDP
- 3-MeO-PCP
- 8A-PDHQ
- Alaproclate
- Amantadine
- Aptiganel
- ARL-12,495
- ARL-15,896-AR
- ARL-16,247
- Budipine
- Delucemine
- Dexoxadrol
- Dextrallorphan
- Dieticyclidine
- Dizocilpine
- Endopsychosin
- Esketamine
- Etoxadrol
- Eticyclidine
- Gacyclidine
- Ibogaine
- Indantadol
- Ketamine
- Ketobemidone
- Lanicemine
- Loperamide
- Memantine
- Methadone (Levomethadone)
- Methorphan (Dextromethorphan
- Levomethorphan)
- Methoxetamine
- Milnacipran
- Morphanol (Dextrorphan
- Levorphanol)
- NEFA
- Neramexane
- Nitromemantine
- Nitrous oxide
- Noribogaine
- Orphenadrine
- PCPr
- Pethidine (meperidine)
- Phencyclamine
- Phencyclidine
- Propoxyphene
- Remacemide
- Rhynchophylline
- Rimantadine
- Rolicyclidine
- Sabeluzole
- Tenocyclidine
- Tiletamine
- Tramadol
- Xenon; Glycine site antagonists: ACEA-1021
- ACEA-1328
- ACC
- Carisoprodol
- CGP-39653
- CKA
- DCKA
- Felbamate
- Gavestinel
- GV-196,771
- Kynurenic acid
- L-689,560
- L-701,324
- Licostinel
- LU-73,068
- MDL-105,519
- Meprobamate
- MRZ 2/576
- PNQX
- ZD-9379; NR2B subunit antagonists: Besonprodil
- CERC-301 (MK-0657)
- CO-101,244 (PD-174,494)
- Eliprodil
- Haloperidol
- Ifenprodil
- Isoxsuprine
- Nylidrin
- Ro8-4304
- Ro25-6981
- Traxoprodil; Polyamine site antagonists: Arcaine
- Co 101676
- Diaminopropane
- Acamprosate
- Diethylenetriamine
- Huperzine A
- Putrescine
- Ro 25-6981; Unclassified/unsorted antagonists: Chloroform
- Cyclopropane
- Diethyl ether
- Diphenidine
- Enflurane
- Ethanol (alcohol)
- Halothane
- Isoflurane
- Methoxyflurane
- Toluene
- Trichloroethane
- Trichloroethanol
- Trichloroethylene
- Xylene
|
|
Kainate
|
- Agonists: 5-Iodowillardiine
- ATPA
- Domoic acid
- Kainic acid
- LY-339,434
- SYM-2081
Antagonists: BGG492
- CNQX
- DNQX
- LY-382,884
- NBQX
- NS102
- Tezampanel
- Topiramate
- UBP-302; Negative allosteric modulators: NS-3763
|
|
Group I
|
- Agonists: Non-selective: ACPD
- DHPG
- Quisqualic acid; mGlu1-selective: Ro01-6128
- Ro67-4853
- Ro67-7476
- VU-71; mGlu5-selective: ADX-47273
- CDPPB
- CHPG
- DFB
- VU-1545
Antagonists: Non-selective: MCPG
- NPS-2390; mGlu1-selective: BAY 36-7620
- CPCCOEt
- LY-367,385
- LY-456,236; mGlu5-selective: CTEP
- DMeOB
- LY-344,545
- Mavoglurant
- SIB-1757
- SIB-1893; Negative allosteric modulators:
- Basimglurant
- Dipraglurant
- Fenobam
- GRN-529
- MPEP
- MTEP
- Raseglurant
|
|
Group II
|
- Agonists: Non-selective: CBiPES
- DCG-IV
- Eglumegad
- LY-379,268
- LY-404,039
- LY-487,379
- MGS-0028; mGlu2-selective: BINA
- LY-566,332
Antagonists: Non-selective: APICA
- EGLU
- HYDIA
- LY-307,452
- LY-341,495
- MCPG
- MGS-0039; mGlu2-selective: PCCG-4
- mGlu3-selective: CECXG; Negative allosteric modulators: Decoglurant
- RO4491533
|
|
Group III
|
- Agonists: Non-selective: L-AP4; mGlu4-selective: PHCCC
- VU-001,171
- VU-0155,041; mGlu7-selective: AMN082; mGlu8-selective: DCPG
Antagonists: Non-selective: CPPG
- MAP4
- MSOP
- MPPG
- MTPG
- UBP-1112; mGlu7-selective: MMPIP
|
|
|
Transporter
(blockers)
|
|
|
Others
|
- Cofactors: α-Ketoglutaric acid
- Iron
- Sulfur
- Vitamin B2
- Vitamin B3
|
|
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
English Journal
- A simplified and accurate method for the analysis of urinary metabolites of testosterone-related steroids using gas chromatography/combustion/isotope ratio mass spectrometry.
- Ouellet A, Leberre N, Ayotte C.SourceLaboratoire de contrôle du dopage, INRS - Institut Armand-Frappier, Laval, Canada, H7V 1B7.
- Rapid communications in mass spectrometry : RCM.Rapid Commun Mass Spectrom.2013 Aug 15;27(15):1739-50. doi: 10.1002/rcm.6620.
- RATIONALE: The analysis of urinary metabolites of testosterone-related steroids through the measurement of their carbon isotopic signature (δ(13) C) by gas chromatography/combustion/mass spectrometry (GC/C/IRMS) is a confirmation method employed in doping control analyses. Stringent analytical cond
- PMID 23821567
- PON1-108 TT and PON1-192 RR genotypes are more frequently encountered in Greek PCOS than non-PCOS women, and are associated with hyperandrogenaemia.
- Paltoglou G, Tavernarakis G, Christopoulos P, Vlassi M, Gazouli M, Deligeoroglou E, Creatsas G, Mastorakos G.Source2nd Department of Obstetrics and Gynaecology, Aretaieion University Hospital, Athens Medical School, Athens, Greece.
- Clinical endocrinology.Clin Endocrinol (Oxf).2013 Aug;79(2):259-66. doi: 10.1111/cen.12139. Epub 2013 May 11.
- OBJECTIVE: To investigate the frequencies of three paraoxonase (PON)1 polymorphisms in Greek polycystic ovary syndrome (PCOS) and non-PCOS women, and their genotypes association with hyperandrogenaemia and insulin resistance.DESIGN: Case-control genetic association study.SETTING: University Hospital
- PMID 23278234
- Inhibitory effects of sigma-1 ligands on handling-induced tachycardia in conscious tethered rats.
- Delaunois A, De Ron P, Detrait E, Guyaux M.SourceDepartment of Non Clinical Development, Non Clinical Safety, UCB Pharma SA, Braine-l'Alleud, Belgium Department of CNS Research, Cognition Pharmacology, UCB Pharma SA, Braine-l'Alleud, Belgium.
- Fundamental & clinical pharmacology.Fundam Clin Pharmacol.2013 Aug;27(4):354-63. doi: 10.1111/j.1472-8206.2012.01042.x. Epub 2012 Apr 5.
- We used conscious tethered Sprague-Dawley rats to evaluate the cardiovascular effects of four sigma-1 (σ1 ) agonists and five antagonists, given alone or in combination. All drugs were administered as a single intraperitoneal dose. The agonists were given at doses reported as efficacious in rodent
- PMID 22486521
Japanese Journal
- Bu-Shen-Ning-Xin decoction suppresses osteoclastogenesis via increasing dehydroepiandrosterone to prevent postmenopausal osteoporosis
- 人工心肺を用いた開胸術によるステロイドホルモンの血中動態
- A case of Cushing's syndrome due to bilateral cortisol-secreting adenomas with unilateral DHEAS oversecretion
Related Links
- デヒドロエピアンドロステロンサルフェート, DHEA-S(dehydroepiandrosterone sulfate ) 測定方法:RIA(チューブ固相法). 外注会社:MCM. 臨床的意義 男性ホルモンの中間 代謝産物である。主に副腎皮質から分泌され(DHEA-Sに関して性腺由来は1%程度)、 ...
- ヒトの副腎皮質からはコルチゾールなどの糖質コルチコイド,アストステロンなどの鉱質 コルチコイドおよび副腎性男性ホルモンであるDHEA,DHEA-S,アンドロステジオンが 分泌されている。副腎皮質ホルモンの分泌には日内変動がある上,ACTH分泌動態を 反映 ...
Related Pictures
★リンクテーブル★
[★]
[正答]
※国試ナビ4※ [100G049]←[国試_100]→[100G051]
[★]
[正答]
※国試ナビ4※ [099D052]←[国試_099]→[099D054]
[★]
- Cushing病と副腎腺腫によるCushing症候群との鑑別に有用でないのはどれか。
[正答]
※国試ナビ4※ [099E059]←[国試_099]→[099E061]
[★]
- 関
- 頚管、ビショップスコア
[★]
- 英
- dehydroepiandrosterone sulfate
- 関
- デヒドロエピアンドロステロン
- 同
- DHEAS
[★]
デヒドロエピアンドロステロン dehydroepiandrosterone
[★]
- 関
- dihydroergotamine mesylate